ADMA Biologics Inc (NASDAQ: ADMA) stock closed at $15.96 on 8/9/24 after a major increase of 30.9%. Moreover, exceptionally high trading volume at 393% of normal accompanied the advance. The stock has been exceptionally strong relative to the market over the last nine months and has risen 30.2% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, ADMA is expected to be a major Value Builder.
ADMA Biologics has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. ADMA Biologics has a slightly negative Appreciation Score of 31 but a very high Power Rating of 99, resulting in the Positive Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment